Crown Bioscience expands portfolio with PreClinOmics acquisition
pharmafile | March 9, 2016 | News story | Manufacturing and Production, Research and Development | cardiovascular, collaboration, crown bioscience, metabolic, preclinomics
Crown Bioscience has announced the acquisition of PreClinOmics, which will see the US-based drug discovery solutions company expand its cardiovascular and metabolic disease (CVMD) portfolios.
PreClinOmics is an in vivo preclinical company who focus on CVMD, as well as renal disease. The Indianapolis-based company was founded in 2001 and this acquisition will see Crown Bioscience add some of the most relevant CVMD models to replicate human disease to its portfolio.
PreClinOmics’s cutting edge technologies that support study designs, including metabolic syndrome, obesity, diabetes and neurology, will join CrownBio’s repertoire. Unlike other commercially available models, for example, their models develop adult onset type 2 diabetes and all the diabetic complications without relying on mutations in the leptin signalling – which have never been identified as relevant to the onset of the human disease.
Jean-Pierre Wery, PhD, president of Crown Bioscience, comments: “The acquisition of PreClinOmics will allow CrownBio to create a centre of excellence in global translational drug development specifically for cardiovascular and metabolic disease. We are confident that the acquisition will ultimately result in greater success in clinical trials and lower the cost of drug development for diseases that produce some of the highest economic costs in the world.”
Joseph Pesek, chief executive officer and co-founder of PreClinOmics, adds: “We are excited vfor the opportunities the acquisition has given us, especially with the reputation that CrownBio has earned with the experience and global resources it offers the market.”
PreClincOmics will now be referred to as “PreClinOmics, a Crown Bioscience company”.
Sean Murray
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
Crown Bioscience opens new US model development centre
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …
